"If There's an Element of Failure, Try to Fail Fast"
In an interview with Business Today's Rajeev Dubey, AstraZeneca's Non-executive Chairman, Leif Johansson talks about how the world's 14th largest pharma company is facing multiple challenges, two of which are Brexit and the US-China trade war
- Dec 24, 2019,
- Updated Dec 25, 2019 7:43 PM IST
The over $22 billion pharma major AstraZeneca has seen one of the most remarkable turnarounds in drug research history. With 144 projects in clinical trials and 16 new molecular entities in final Phase-III trials, it boasts of a new drugs pipeline bigger than that of rivals Pfizer and Roche - both more than double its size in revenue. Yet, the world's 14th largest pharma company faces multiple challenges, two of which are Brexit and the US-China trade war (18% revenue from China and 30% from the US). Business Today's Rajeev Dubey caught up with AstraZeneca's Non-executive Chairman, Leif Johansson, during his recent India visit. Edited Excerpts:
The over $22 billion pharma major AstraZeneca has seen one of the most remarkable turnarounds in drug research history. With 144 projects in clinical trials and 16 new molecular entities in final Phase-III trials, it boasts of a new drugs pipeline bigger than that of rivals Pfizer and Roche - both more than double its size in revenue. Yet, the world's 14th largest pharma company faces multiple challenges, two of which are Brexit and the US-China trade war (18% revenue from China and 30% from the US). Business Today's Rajeev Dubey caught up with AstraZeneca's Non-executive Chairman, Leif Johansson, during his recent India visit. Edited Excerpts: